Immunotherapy and combination treatments for triple-negative breast cancer: a Scopus bibliometric perspective.

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-21 DOI:10.1080/14796694.2025.2531429

Ninie Nadia Zulkipli, Imilia Ismail, Wan Rohani Wan Taib, Sarina Sulong

{"title":"Immunotherapy and combination treatments for triple-negative breast cancer: a Scopus bibliometric perspective.","authors":"Ninie Nadia Zulkipli, Imilia Ismail, Wan Rohani Wan Taib, Sarina Sulong","doi":"10.1080/14796694.2025.2531429","DOIUrl":null,"url":null,"abstract":"Background: Immunotherapy, a cornerstone treatment for triple-negative breast cancer (TNBC), has several limitations as a monotherapy. Global research is actively investigating effective combinatorial immunotherapy treatments for TNBC. Aim: This study aimed to elucidate an overview and research hot spots of immunotherapy and its combinatorial regimens in TNBC management for the past 5 years.Materials & methods: Publications were retrieved from Scopus from 2019 to 2023 and analyzed using Harzing's Publish or Perish, Microsoft Excel, and VOSviewer.Results: The study included a total of 1,818 publications, demonstrating increased publication trends over the years. The most productive continent, country, and journal were Asia (TP = 957), the United States (TP = 653), and Cancers (TP = 123), respectively. The United States and China exhibited the most dynamic inter-country collaboration, evidenced by the highest link strength (69). The United States emerged as the most influential country, recording the highest TLS (520). The analysis of co-occurrence author keywords revealed ICIs, PD-L1, and TME as research hot spots. The thorough integration of knowledge and research on these hot spots may offer an alternative in the management of TNBC.Conclusion: It is imperative to identify combinatorial immunotherapy treatments in order to have better cancer management.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2593-2604"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344806/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2531429","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Immunotherapy, a cornerstone treatment for triple-negative breast cancer (TNBC), has several limitations as a monotherapy. Global research is actively investigating effective combinatorial immunotherapy treatments for TNBC. Aim: This study aimed to elucidate an overview and research hot spots of immunotherapy and its combinatorial regimens in TNBC management for the past 5 years.

Materials & methods: Publications were retrieved from Scopus from 2019 to 2023 and analyzed using Harzing's Publish or Perish, Microsoft Excel, and VOSviewer.

Results: The study included a total of 1,818 publications, demonstrating increased publication trends over the years. The most productive continent, country, and journal were Asia (TP = 957), the United States (TP = 653), and Cancers (TP = 123), respectively. The United States and China exhibited the most dynamic inter-country collaboration, evidenced by the highest link strength (69). The United States emerged as the most influential country, recording the highest TLS (520). The analysis of co-occurrence author keywords revealed ICIs, PD-L1, and TME as research hot spots. The thorough integration of knowledge and research on these hot spots may offer an alternative in the management of TNBC.

Conclusion: It is imperative to identify combinatorial immunotherapy treatments in order to have better cancer management.

查看原文本刊更多论文

免疫疗法和联合治疗三阴性乳腺癌：Scopus文献计量学的观点。

背景：免疫疗法是治疗三阴性乳腺癌（TNBC）的基础疗法，但作为单一疗法存在一些局限性。全球研究正在积极探索有效的联合免疫治疗TNBC。目的：本研究旨在阐述近5年来免疫治疗及其联合治疗方案在TNBC治疗中的概况和研究热点。材料与方法：从Scopus检索2019年至2023年的出版物，使用Harzing's Publish or Perish、Microsoft Excel和VOSviewer进行分析。结果：该研究共包括1818份出版物，显示出多年来出版物数量增加的趋势。研究成果最多的大洲、国家和期刊分别是亚洲（TP = 957）、美国（TP = 653）和癌症（TP = 123）。美国和中国展示了最具活力的国家间合作，最高的联系强度证明了这一点（69）。美国成为最具影响力的国家，获得了最高的TLS（520）。共现作者关键词分析显示，ICIs、PD-L1和TME是研究热点。这些热点的知识和研究的深入整合可能为TNBC的管理提供另一种选择。结论：确定联合免疫治疗方案是提高肿瘤治疗效果的必要条件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.